Approach to Diagnosis and Management of Hereditary Angioedema (HAE) in Pediatrics

Hereditary Angioedema (HAE) Master Suite

Chief Mentor: Dr. A. Narendra (Assistant Professor, Pediatrics)

Pediatric Allergy & Immunology Postgraduate Clinical Framework

MD / DNB Core Rounds

Bradykinin-Mediated Angioedema: Diagnostic Rigor

"Residents and interns, differentiating bradykinin-mediated angioedema from histamine-driven allergic swelling is a critical, life-saving skill. HAE does not respond to adrenaline, steroids, or antihistamines. Master this systematic complement assay interpretation and multi-tiered management approach for your exams and emergency duties."

— Dr. A. Narendra

High-Yield Diagnostic Workup

Pathophysiological Divergence: HAE is caused by autosomal dominant mutations in the **SERPING1 gene**, causing a deficiency or dysfunction of the **C1 esterase inhibitor (C1-INH)**. This leads to unregulated plasma kallikrein activation and massive overproduction of **bradykinin**, a potent vasodilator.

Clinical Feature	HAE (Bradykinin-Mediated)	Allergic Angioedema (Histaminergic)
Urticaria (Wheals) / Pruritus	Absent (Key clinical sign)	Prominently Present
Prodrome	**Erythema marginatum** (non-pruritic serpiginous rash)	None or generalized itching
Onset & Duration	Slow onset (hours), resolves slowly over 2-5 days	Rapid onset (minutes), resolves within 24 hours
Abdominal Attacks	Severe abdominal colic/pain due to intestinal wall edema	Absent or mild systemic anaphylaxis signs
Response to Adrenaline/Steroids	Completely Unresponsive	Excellent, rapid response

Primary Screening Test: **Serum C4 levels**. C4 is almost universally **low** in all HAE patients, even during asymptomatic periods between attacks. If C4 is normal during an active swelling episode, HAE is highly unlikely.

Systemic Matrix for Differentiating HAE Types:

HAE Type I (85% of cases)

• Mechanism: Reduced production of C1-INH protein.
• Serum C4: Decreased
• C1-INH Protein Level: **Decreased**
• C1-INH Functional Assay: Decreased

HAE Type II (15% of cases)

• Mechanism: Normal levels of a dysfunctional C1-INH protein.
• Serum C4: Decreased
• C1-INH Protein Level: **Normal or Elevated**
• C1-INH Functional Assay: **Decreased** (Crucial diagnostic test)

Note on HAE with Normal C1-INH: Formerly Type III, mostly seen in females, linked with estrogen modifications (pregnancy, oral contraceptives) and mutations in Factor XII, plasminogen, or kininogen genes. C4, C1-INH levels, and function are all normal.

Therapeutic Intervention Protocols

1. Acute On-Demand Therapy (Emergency Abatement)

The immediate clinical priority during an attack, especially if localized to the airway (laryngeal edema) or causing excruciating bowel pain, is blocking the bradykinin cascade:

• Plasma-Derived or Recombinant C1-INH Concentrate (Berinert / Cinryze / Ruconest): First-line replacement therapy. Restores immediate inhibitor checkpoints. Dose: **20 Units/kg IV**. Approved across pediatric age ranges.
• Icatibant (Firazyr): A selective **Bradykinin B2 receptor antagonist**. Administered subcutaneously. Extremely effective for self-administration in older children and adolescents.
• Ecallantide (Kalbitor): A potent recombinant plasma **kallikrein inhibitor**. Approved for children aged 12 years and older.
• Emergency Fallback (Fresh Frozen Plasma - FFP): If targeted biologics are unavailable in the emergency room, administer FFP (2 bags/10-15 mL/kg). *Caveat:* Classically carries a small theoretical risk of exacerbating the attack by supplying additional kininogen substrate, though clinically verified as a vital rescue fallback.

2. Short-Term and Long-Term Prophylaxis (LTP)

Short-Term Prophylaxis (STP):

Indicated before dental work, endoscopies, intubations, or major surgeries. Administer **C1-INH Concentrate 1-2 hours prior** to the procedure. If unavailable, use high-dose oral danazol or fresh frozen plasma.

Long-Term Prophylaxis (LTP) Agents:

• Lanadelumab (Takhzyro): A human monoclonal antibody targeting active **plasma kallikrein**. Administered subcutaneously every 2-4 weeks. Extremely well-tolerated and approved down to age 2 years.
• Berotralstat (Orladeyo): An oral, once-daily plasma kallikrein inhibitor approved for adolescents aged 12 years and older.
• Subcutaneous C1-INH (Haegarda): Used twice weekly for targeted suppression of breakthrough events.
• Attenuated Androgens (Danazol / Stanozolol): Increases hepatic synthesis of C1-INH. Avoided or heavily restricted in pediatric cohorts due to major virilization, premature epiphyseal fusion, hepatic tumors, and lipid abnormalities.

Interactive Board MCQ Hub

Q1. Hereditary Angioedema Types I and II are caused by mutations in the SERPING1 gene, leading to the excessive vascular accumulation of which primary mediator?

A) Histamine B) Bradykinin C) Leukotriene D4 D) Prostaglandin D2

Q2. Which of the following clinical features is almost universally ABSENT during an active swelling attack in a patient with classic HAE?

A) Laryngeal edema B) Severe abdominal pain C) Pruritic urticarial wheals (Hives) D) Asymmetric extremity swelling

Q3. Which complement pathway component serves as the absolute initial lab screening tool of choice for HAE due to its persistent subnormal levels?

A) C3 B) Serum C4 level C) C5 D) Factor B

Q4. A 6-year-old child presents with low C4, normal quantitative antigenic C1-INH protein levels, but profoundly low C1-INH functional activity. What is the correct diagnostic class?

A) HAE Type I B) HAE Type II C) Allergic Angioedema spectrum D) Acquired Angioedema (AAE)

Q5. Which non-pruritic, serpiginous skin rash serves as a classic prodromal warning indicator before an HAE swelling event?

A) Erythema multiforme B) Erythema marginatum C) Erythema infectiosum D) Livedo reticularis

Q6. Icatibant (Firazyr) acts as an effective rescue medication for acute HAE attacks via which specific pharmacodynamic action?

A) Direct activation of C1 esterase inhibitor production B) Selective competitive antagonism of the Bradykinin B2 receptor C) Monoclonal antibody blockade of active plasma kallikrein D) H1 histamine receptor stabilization

Q7. What human monoclonal antibody targeting active plasma kallikrein is highly effective for Long-Term Prophylaxis (LTP) in children as young as 2 years old?

A) Lanadelumab (Takhzyro) B) Ecallantide C) Berotralstat D) Rituximab

Q8. Why are attenuated androgens like Danazol heavily restricted and generally avoided for long-term management in pediatric HAE cohorts?

A) They accelerate the viral breakdown of functional complement factors B) Risk of virilization, lipid disturbances, and premature epiphyseal fusion causing short stature C) Complete lack of clinical efficacy in increasing liver protein production D) High rates of acute renal failure in children

Q9. Before an elective dental extraction or intubation procedure, what is the preferred Short-Term Prophylaxis (STP) option for a confirmed HAE child?

A) High-dose oral antihistamines given 30 minutes prior B) Intravenous administration of C1-INH Concentrate 1-2 hours prior C) Intramuscular Adrenaline immediately before the incision D) Avoid the dental procedure entirely

Q10. If an HAE patient presents to a rural emergency department with severe laryngeal edema and targeted biologics or C1-INH concentrates are completely unavailable, what is the next best rescue fluid intervention?

A) Hydrocortisone IV push B) Infusion of Fresh Frozen Plasma (FFP) C) Packed Red Blood Cells (PRBC) cross-matched D) High-volume Normal Saline boluses

Quiz Performance Tracker

0 / 10

Updates instantly as you verify answers inside the MCQs tab.

Pathology Quick-Check

SERPING1 Mutation Axis: Deficient C1-INH $\rightarrow$ Unchecked conversion of Prekallikrein $\rightarrow$ Kallikrein $\rightarrow$ Excessive High Molecular Weight Kininogen cleavage $\rightarrow$ **Bradykinin Surge** $\rightarrow$ Endothelial B2 Receptor binding $\rightarrow$ Severe localized fluid extravasation.

Dr. Narendra's PG Pearls

"Residents, remember this high-yield differentiator for your clinical exams: if an adolescent presents to the emergency room with significant facial and lip swelling accompanied by severe abdominal distress, and you find a **normal C3 level alongside a profoundly decreased C4 level**, your primary working diagnosis must be **Hereditary Angioedema**. The classical complement pathway is activated up to the C4 step, leaving the alternative pathway (C3) completely untouched."